Other and unspecified disorders of lactation
Conditions
Interventions
50 people will be invited with indication of suppression of lactation. Through a lottery, 25 people will be selected for the physical measures group and 25 people for the Cabergolina group.
Participan
Drug
Other
D01.045.250.875.400
E02.319
Sponsors
Instituto de Medicina Integral Prof. Fernando Figueira
Instituto de Medicina Integral Prof. Fernando Figueira
Eligibility
Sex/Gender
Female
Age
10 Years to 55 Years
Inclusion criteria
Inclusion criteria: Women with up to 24 hours postpartum; gestational age at delivery of 20 weeks or more; indication for inhibition of lactation: late fetal loss, neomorto up to 24 hours, breast cancer or leukemia in pregnancy or in case of severe maternal morbidity
Exclusion criteria
Exclusion criteria: Hypertensive syndromes in current gestation; known hypersensitivity to cabergoline; history of cardiac valve disease; history of retroperitoneal or pulmonary fibrotic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severe breast pain is expected to occur in less than 10% of patients. Measurement scale will determine the intensity of the symptoms;Severe engorgement is expected to occur in less than 10% of patients. Measurement scale will determine the intensity of the symptoms;Severe spontaneous papillary discharge is expected to occur in less than 10% of patients. Measurement scale will determine the intensity of the symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| Decreased frequency of adverse effects to less than 1%. Adverse effects will be investigated through interviews;Decreased complications to less than 1%. Complications will be assessed through clinical examination;There will be no change in blood pressure. Blood pressure will be measured before and one hour after the intervention | — |
Countries
Brazil
Contacts
Public ContactFlávio Silva
Instituto de Medicina Integral Prof. Fernando Figueira
Outcome results
None listed